HONG KONG – With five drugs in its pipeline and a deal with big pharma worth tens of millions of dollars, Singapore drug developer Aslan Pharmaceuticals Pte Ltd. aims to tap the markets in Taiwan, looking to overcome some flagging investor sentiment on biopharma.